Odonate Therapeutics Inc (NASDAQ:ODT) CEO Kevin C. Tang purchased 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 12th. The shares were purchased at an average price of $15.60 per share, for a total transaction of $312,000.00. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.
ODT stock opened at $15.12 on Friday. Odonate Therapeutics Inc has a one year low of $14.06 and a one year high of $32.00.
Odonate Therapeutics (NASDAQ:ODT) last posted its quarterly earnings data on Tuesday, October 23rd. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by ($0.02). Equities analysts forecast that Odonate Therapeutics Inc will post -3.49 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc lifted its holdings in Odonate Therapeutics by 18.5% during the third quarter. Vanguard Group Inc now owns 316,733 shares of the company’s stock valued at $6,148,000 after purchasing an additional 49,528 shares in the last quarter. Federated Investors Inc. PA purchased a new position in Odonate Therapeutics during the third quarter valued at $68,000. Vanguard Group Inc. lifted its holdings in Odonate Therapeutics by 18.5% during the third quarter. Vanguard Group Inc. now owns 316,733 shares of the company’s stock valued at $6,148,000 after purchasing an additional 49,528 shares in the last quarter. Tang Capital Management LLC lifted its holdings in Odonate Therapeutics by 11.2% during the third quarter. Tang Capital Management LLC now owns 13,796,747 shares of the company’s stock valued at $267,795,000 after purchasing an additional 1,384,409 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Odonate Therapeutics by 222.8% in the third quarter. Tower Research Capital LLC TRC now owns 5,288 shares of the company’s stock worth $102,000 after buying an additional 3,650 shares in the last quarter. 92.23% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2018/12/16/insider-buying-odonate-therapeutics-inc-odt-ceo-buys-312000-00-in-stock.html.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.
Featured Story: Why Dividend Stocks May Be Right for You
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.